| Date Filed | Type | Description |
| 10/05/2023 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 372,671 options to buy
@ $0.24, valued at
$89.4k
|
|
| 03/31/2023 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 41,065 options to buy
@ $1.05, valued at
$43.1k
|
|
| 10/11/2022 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Bought 30,000 shares
@ $1.29, valued at
$38.7k
|
|
| 10/07/2022 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 74,878 options to buy
@ $1.25, valued at
$93.6k
|
|
| 04/22/2022 |
4
| Sukhtian Faisal Ghiath (10% Owner) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Acquired 27,982,529 shares
@ $0 |
|
| 03/24/2022 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 21,878 options to buy
@ $1.92, valued at
$42k
|
|
| 12/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/20/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/26/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/17/2020 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $0.6731, valued at
$6.7k
|
|
| 07/21/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/20/2020 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $0.54, valued at
$8.1k
|
|
| 10/07/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/05/2019 |
4
| BioLexis Pte Ltd. (10% Owner) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 4,288,624 shares
@ $0.9327, valued at
$4M
|
|
| 01/03/2019 |
4
| BioLexis Pte Ltd. (10% Owner) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 4,288,624 shares
@ $0.9327, valued at
$4M
|
|
| 12/31/2018 |
4
| BioLexis Pte Ltd. (10% Owner) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Acquired 1,505 convertible preferred
@ $0 |
|
| 12/31/2018 |
4/A
| BioLexis Pte Ltd. (10% Owner) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Acquired 1,468 convertible preferred
@ $0 |
|
| 12/06/2018 |
4
| BioLexis Pte Ltd. (10% Owner) has filed a Form 4 on Outlook Therapeutics, Inc.|
Txns:
| Granted 4,288,624 shares
@ $0.9327, valued at
$4M
|
|
| 11/09/2018 |
4
| BioLexis Pte Ltd. (10% Owner) has filed a Form 4 on Oncobiologics, Inc.|
Txns:
| Granted 8,577,248 shares
@ $0.9327, valued at
$8M
|
|
| 10/02/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/02/2017 |
4
| Sukhtian Faisal Ghiath (Director) has filed a Form 4 on Oncobiologics, Inc.|
Txns:
| Granted 25,000 options to buy
@ $1.26, valued at
$31.5k
|
|
| 09/18/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |